Opioid Use Disorder Market Size (2024 – 2030)

The Global Opioid Use Disorder Market was valued at USD 3.21 billion and is projected to reach a market size of USD 6.54 billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 10.7%.

Opioids, which are medically used to treat pain, have detrimental effects on the central nervous system and analgesic function as well as the ability to cause euphoria. Opioid use disorder is often a chronic, recurrent illness linked to considerably increased rates of morbidity and death. The market for the treatment of opioid use disorder is primarily driven by the expanding number of patients with opioid-related addiction, greater government initiatives, and increased support from NGOs and agencies. However, the difficulty of individuals to pursue treatment methods and the abandonment of behavioral treatments that cause relapse are the factors that restrict the growth of this market. Government programs and financing are crucial resources for this industry.

Key Market Insights:

By building a cutting-edge, real-world evidence method, Orexo AB announced its cooperation with ApexB.io and Magellan Rx Management to further research the usage of modia, a digital therapy created for people with opioid use disorder (OUD). Through their computer or mobile device, people with OUD may get customized, interactive psychotherapy sessions thanks to Modia.

The acquisition of Opiant Pharmaceuticals, Inc. by Indivior PLC has been finalized. Investigational opioid overdose therapy candidate OPNT003 is offered by Opiant. The purchase will improve Indivior's standing in the field of addiction therapy.

Global Opioid Use Disorder Market Drivers:

Growing Recognition of Buprenorphine Patches as a Successful Treatment Approach to Drive Market Expansion:

Recently, there has been a rise in demand for patches used to treat opioid addiction. For the treatment of opioid use disorder, these patches are recognized as an effective therapeutic. Transdermal patches have several benefits that are common and self-administered, including improving the mechanism of medication administration and reducing discomfort. These transdermal patches can also be a viable substitute for people who need 24/7 opioid medication for OUD. For instance, WellSpan Health and York Opioid Collaborative collaborated in 2009 to create a clinical trial to create a Lidocaine patch for OUD therapy. During the projection period, it is projected that these collaborations will hasten the acceptance of various therapies. Additionally, a larger influx of new patients is predicted to fuel the expansion of the global market for opioid use disorder (OUD).

Increasing Cases of Opioid Addiction to Increase Market Share:

Currently, the world's population suffers from a variety of severe and chronic illnesses, including cancer, cardiovascular ailments, and other maladies. To address these illnesses, patients use painkillers, typically opioids. Patients who utilize drugs frequently develop drug addictions. As a result of their abrupt discontinuation and developing dependency on certain drugs, the patients could experience drug withdrawal symptoms. For instance, the National Drug Dependence Treatment Centre (NDDTC)'s Magnitude of Substance Use in India report, which was released in February 2019, estimates that 2.06% of Indians currently use opioids, with about 0.55% of them likely needing assistance due to opioid use issues (harmful use and dependence). The frequency of OIJD has grown globally along with the prevalence of opioid addiction. For instance, the CDC estimates that in the United States in 2021, 2.7 million persons aged 12 or older will report having OUD. These elements increase the risk that patients would suffer disastrous consequences, such as opioid overdose death.

Global Opioid Use Disorder Market Challenges:

Adverse OUD Drug Effects to Limit Market Growth:

The market is likely to face challenges during the forecast period as a result of the negative effects of the medications used to treat opioid addiction. These medications frequently cause muscular pains, nausea, vomiting, diarrhea, constipation, respiratory problems, bone/joint pain, bladder discomfort, and cramping in the abdomen. In addition, when a medication response is strong, the patient may also experience depression and other psychological issues. Additionally, the U.S. FDA has issued a warning due to the hazards connected with these pharmaceuticals, which hurts the drug class and decreases the uptake of treatments for OIJD.  For instance, the U.S. FDA issued a warning in January 2022 regarding dental issues with OUD and pain medication buprenorphine that is dissolved in the mouth. Dental problems, such as cavities, tooth decay, oral infections, and tooth loss, can be significant and have been documented in individuals who have no prior history of dental problems. Such elements could to some extent limit market expansion.

Global Opioid Use Disorder Market Opportunities:

Government and non-government organizations are putting more emphasis on raising awareness to support industry growth.

Another key reason fueling the market rise is the increasing involvement of governmental and non-governmental organizations in raising awareness about opioid overdose and its dangers. Numerous organizations have expanded their efforts to address the issue as a result of the sharp rise in the number of opioid addicts. To help patients and decrease the effects of opioid dependency, several countries have increased their efforts. For instance, Health and Human Services (HHS) announced money for drug abuse prevention and treatment initiatives in March 2022. The action was done to increase access to medication-assisted therapy for opioid use disorder and curb prescription drug abuse. It is predicted that similar programs would motivate more people with opioid-related problems to seek treatment. These elements are likely to benefit the global market during the anticipated time frame.

OPIOID USE DISORDER MARKET REPORT COVERAGE:

Global Opioid Use Disorder Market Segmentation: By Drug

• Buprenorphine

  • Sublocade

  • Belbuca

  • Suboxone

  • Zubsolv

• Methadone

• Naltrexone

The market is divided into methadone, buprenorphine, and naltrexone based on the drug class. In 2022, the buprenorphine market category held the greatest market share by 36%. The sector is dominant because there are many branded medications in this category and because these drugs are used more often in developed markets like the U.S. and France. SUBLOCADE, SUBOXONE, and ZUBSOLV are a few of the crucial buprenorphine medications. Due to the rising number of generic product launches and the segment's relative dearth of new product launches, it is projected that the methadone market will expand at a slower rate by 23%. A very small number of product options will cause the naltrexone sector to have a smaller market share over the projection period.

Global Opioid Use Disorder Market Segmentation: By Route of Administration

• Intravenous

• Oral

The market is divided into oral and parenteral segments based on the route of administration. Due to the availability of many types of OUD medications in varied doses in the parenteral form, the parenteral segment is anticipated to have the largest market share throughout the course of the projection period by 53%. As a result, the parenteral method of medication delivery continues to rule the market. The market share of oral medications for opioid use disorder is anticipated to decline globally. However, given that so many people prefer oral medicine delivery versus injection, it is anticipated to rise significantly.

Global Opioid Use Disorder Market Segmentation: By Age

• 19 to 40

• 41 to 60

• 61 & over

Market segments for opioid use disorders include those aged 19 to 40, 41 to 60, and 61 and older. Due to changes in living patterns and growth in the use of opioids as a pain reliever among young and middle-aged people, the 19 to 40 age group segment led the market in 2022, and it is anticipated that this trend will continue during the projection period by 42%.

Global Opioid Use Disorder Market Segmentation: By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies & Stores

• Online Pharmacies

The market is divided into hospital pharmacies, retail pharmacies & and stores, and internet pharmacies based on the distribution channel. As a result of the patient population's reliance on this channel for the administration of parenteral OUD medications like buprenorphine, the hospital pharmacy sector will likely have a larger part of the worldwide market by 39%. Due to the dependence of the patient population on these sites for filling their prescriptions, the retail pharmacies & and shops category is predicted to grow to be the second-largest segment throughout the next years. On the other hand, the Internet pharmacy market is predicted to develop at the greatest CAGR as more patients begin choosing these locations to get their medications due to the convenience they offer.

Global Opioid Use Disorder Market Segmentation: By Region

• North America

• Europe

• Asia-Pacific

• South America

• Middle East and Africa

North America is likely to dominate over the projected period by 45%. This is because a sizable portion of Americans suffer from opioid dependence, important actors are present in the area, and regional governments are becoming more actively involved in fighting the pandemic. For instance, the National Centre for Biotechnology Information (NCBI) reported in 2020 that the number of Americans suffering from opioid use disorder is thought to be over 2.1 million.

According to projections, Europe will come in second on the global market. This can be attributed to the region's increased new product releases as well as the rise in patients with opioid dependence.

Due to the rise in public awareness of the disease, the Asia Pacific market is anticipated to have the highest CAGR throughout the forecast period. Additionally, it is anticipated that the region's rising healthcare spending will fuel market expansion.

The remainder of the globe is made up of areas like South America the Middle East and Africa that previously had a smaller market share. However, the rise in patients with opioid dependence, rising healthcare costs, and rising public awareness are anticipated to spur market expansion in the years to come.

COVID-19 Impact on Global Opioid Use Disorder Market:

On the development of the OIJD market, the COVID-19 epidemic is predicted to have a conflicting effect. The epidemic has put a strain on the global healthcare system. Due to the COVID-19 patients receiving priority care, all elective procedures were postponed in 2020. The need for opioids for pain management was predicted to decline as there were fewer operations scheduled, which led to a decline in OUD prevalence. However, during the pandemic, the cancellation of doctor's appointments led to a rise in long-term opioid use. OUD illness thereafter became more common as a result. In the US, the most common injury-related cause of death is opioid overdose. In the United States, the CDC predicts that 2.7 million people will have OUD by 2020. As a result, there was not a major increase in new opioid users, but the market developed as existing users continued to take the drug.

Global Opioid Use Disorder Market Recent developments:

A class of medications known as opioids is used to relax muscles, lessen pain, and relieve tension. Opioid use disorder is a chronic, relapsing brain disease that is characterized by excessive opioid use, despite its negative side effects. Because it involves functional alterations to brain circuits associated with motivation, stress, self-control, and decision-making, and because those changes may persist for a long time after drug use has ended, it is recognized as a brain condition. The signs of opioid use disorder include a strong want to take opioids, a rise in opioid tolerance, and withdrawal symptoms after stopping. The market is likely to grow as a result of rising opioid prescriptions, rising OUD awareness among the populace, rising government activities to identify and treat OUD, and rising product approvals for OIJD treatment medications. For instance, the Swedish Medical Products Agency (MPA) approved Subutex in May 2020, according to Indivior PLC, a pharmaceutical firm based in the United States. Injections of 100 and 300 mg of Subutex, a sustained-release solution, are available for the replacement therapy of opioid dependency in adults and adolescents older than 16 years old.

 Key Players:

1. Alkermes

2. Indivior PLC

3. BioDelivery Sciences International

4. Orexo US

5. Titan Pharmaceuticals

6. Omeros Corporation

7. Camurus

8. Hikma Pharmaceuticals PLC

9. AstraZeneca plc

10. Viatris Inc

• In June 2022: To build a multichannel digital marketing strategy across the United States and improve their capability of giving Probuphine implants to those suffering from opioid addiction, Titan Pharmaceuticals, Inc. partnered with Indegene.

• In April 2023: The Buprenorphine Assistance Pilot Programme was introduced by the New York State Department of Health (DOH) and New York State Office of Addiction Services and Supports (OASAS) to help with the expense of buprenorphine for OUD treatment.